Correlation Between Cue Biopharma and Oculis Holding

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Cue Biopharma and Oculis Holding at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cue Biopharma and Oculis Holding into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cue Biopharma and Oculis Holding AG, you can compare the effects of market volatilities on Cue Biopharma and Oculis Holding and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cue Biopharma with a short position of Oculis Holding. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cue Biopharma and Oculis Holding.

Diversification Opportunities for Cue Biopharma and Oculis Holding

0.93
  Correlation Coefficient

Almost no diversification

The 3 months correlation between Cue and Oculis is 0.93. Overlapping area represents the amount of risk that can be diversified away by holding Cue Biopharma and Oculis Holding AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oculis Holding AG and Cue Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cue Biopharma are associated (or correlated) with Oculis Holding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oculis Holding AG has no effect on the direction of Cue Biopharma i.e., Cue Biopharma and Oculis Holding go up and down completely randomly.

Pair Corralation between Cue Biopharma and Oculis Holding

Considering the 90-day investment horizon Cue Biopharma is expected to generate 3.51 times more return on investment than Oculis Holding. However, Cue Biopharma is 3.51 times more volatile than Oculis Holding AG. It trades about 0.13 of its potential returns per unit of risk. Oculis Holding AG is currently generating about 0.15 per unit of risk. If you would invest  66.00  in Cue Biopharma on August 31, 2024 and sell it today you would earn a total of  56.00  from holding Cue Biopharma or generate 84.85% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Strong
Accuracy100.0%
ValuesDaily Returns

Cue Biopharma  vs.  Oculis Holding AG

 Performance 
       Timeline  
Cue Biopharma 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Cue Biopharma are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Cue Biopharma exhibited solid returns over the last few months and may actually be approaching a breakup point.
Oculis Holding AG 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Oculis Holding AG are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady fundamental indicators, Oculis Holding unveiled solid returns over the last few months and may actually be approaching a breakup point.

Cue Biopharma and Oculis Holding Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Cue Biopharma and Oculis Holding

The main advantage of trading using opposite Cue Biopharma and Oculis Holding positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cue Biopharma position performs unexpectedly, Oculis Holding can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oculis Holding will offset losses from the drop in Oculis Holding's long position.
The idea behind Cue Biopharma and Oculis Holding AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.

Other Complementary Tools

Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.